Glaucoma is a leading cause of irreversible blindness around the world. And today, laser treatment for this progressive condition is getting much-needed attention, thanks to a user-friendly website from Lumibird Medical: www.glaucoma-laser-assisted-solutions.com.
As a world leader in ophthalmic lasers, Lumibird developed this platform to provide a better understanding of laser technologies, indications for use and clinical applications in glaucoma management. Astute readers will notice the website’s name spells out GLASS, which is the acronym for Lumibird’s glaucoma laser-assisted solutions, which offer options at every disease stage. These include selective laser trabeculoplasty (SLT) for first-line treatment, SubCyclo as a second-line, and ThermoCyclo as a last resort.
Selective laser trabeculoplasty is a non-destructive and repeatable therapy used to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). Its efficacy, along with the cost-savings benefit and improved quality of life for patients, was confirmed in 2019’s LIGHT study.
SubCyclo is a subthreshold laser-therapy that stimulates the ciliary body with an intermittent 810nm laser wavelength. This lowers IOP by reducing aqueous humor production and remodeling the uveoscleral pathway to provide an improved secondary route of aqueous outflow.
Finally, Thermocyclo is a well-established transscleral laser treatment indicated for refractory glaucoma patients. This laser uses transscleral photocoagulation of the ciliary processes to reduce overall production of aqueous humor.
The website is currently available in English; a Spanish version will be available in April.
